Injective (INJ) is currently priced at $2.90, reflecting a 1.69% increase over the past 24 hours, with a daily trading range of $2.78 to $2.92. The volume stands at approximately 39.3 million, which represents 13.54% of the market cap, indicating a moderate trading interest in the asset.

The hourly moving averages show a positive short-term trend, with the 8 SMA at $2.89 (+0.42%) and the 13 SMA at $2.86 (+1.28%). However, the 144 SMA at $2.96 indicates a potential resistance level, as it has a negative change of -1.97%, suggesting a short-term pullback might be on the horizon.

The 1-hour RSI is at 74, indicating that INJ is in overbought territory, which often leads to price corrections. In contrast, the 7-day RSI at 47 suggests that the asset is neither overbought nor oversold, with the 7-day price change showing a decline of 3.5%.

Fundamentally, INJ's price has decreased significantly over the past two weeks, with a 14-day change of -15.90% and a 30-day change of -8.21%. This downward trend in the longer time frames indicates that market sentiment may be weakening despite the recent short-term uptick.

In conclusion, while the short-term indicators suggest potential upward momentum, the overbought condition coupled with the negative long-term price trends indicates caution. Therefore, the rating for Injective (INJ) is a Hold, as it may be prudent to wait for a more favorable entry point or confirmation of a trend reversal before considering a buy.